華潤醫藥(03320.HK):博雅生物股份被凍結 收購條件未達成
華潤醫藥(03320.HK)表示,就收購博雅生物製藥(300294.SZ)集團控股權,博雅生物近日披露,賣方捲入有關其結欠平安證券債務的法律糾紛,平安證券向法院申請財產保全,截至2月10日賣方持有目標公司合共1.03億股非限售流通股份被司法凍結,佔目標公司總股本的24.39%。
公司表示,由於收購交易須待若干先決條件獲達成後方可作實,截至目前,除於目標公司股東大會上批准發行股份,以及及國家市場監督管理總局反壟斷局通過經營者集中審查外,所有其他先決條件尚 未獲達成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.